Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Background Linezolid is a bacteriostatic oxazolidinone antibiotic that has been proven to be effective for the treatment of patients with pneumonia, skin and soft tissue infections, and possibly bacteraemia, due to Gram-positive cocci. However, the drug is sometimes used for the treatment of patients with endocarditis due to Gram-positive cocci resistant to other antibiotics. Methods We carried out a review of the available literature to evaluate whether linezolid is also effective for the treatment of patients with infective endocarditis. Results We identified 23 case reports and 3 case series reporting the experience with 56 patients with endocarditis treated with linezolid. Evaluable data for 33 patients who received linezolid and for whom individual patient data were reported were further analysed. Prosthetic valve infective endocarditis accounted for 25% of the reviewed cases. Methicillin-resistant Staphylococcus aureus and vancomycin-intermediate S. aureus were the most commonly isolated cocci (24.2% and 30.3% of cases, respectively). Linezolid alone was administered to 66.7% of patients while the rest received the antibiotic in combination with rifampicin, gentamicin, fusidic acid or amikacin. A total of 63.6% (21/33) of patients with endocarditis were cured after linezolid administration. The overall and endocarditis-related mortality was 33.3% (11/33) and 12.1% (4/33), respectively. Thrombocytopenia developed in 30.8% (8/26) of patients for whom relevant data were av…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a small number of patients, linezolid was effective therapy of vancomycin-resistant E faecium IE. 174”
Citations
Cites
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Bolger, A. F., Levison, M. E., Ferrieri, P., Gerber, M. A., Tani, L. Y., Gewitz, M. H., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.165564 · Cited by 1,707
Infective Endocarditis in Adults
Mylonakis, E., & Calderwood, S. B. (2001) · New England Journal of Medicine · doi:10.1056/nejmra010082 · Cited by 1,324
Moreillon, P., & Que, Y.-A. (2004) · The Lancet · doi:10.1016/s0140-6736(03)15266-x · Cited by 861
Howden, B. P., Ward, P. B., Charles, P. G. P., Korman, T. M., Fuller, A., Cros, P. D., Grabsch, E. A., Roberts, S. A., Robson, J., Read, K., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/381202 · Cited by 484 · cited 2×
“2006 (4) M 46 RA, AV and MV replacement possible abscess in the mitral-aortic area CoNS VAN, RIF ( 15 ),”
Birmingham, M. C., Rayner, C. R., Meagher, A. K., Flavin, S. M., Batts, D. H., & Schentag, J. J. (2003) · Clinical Infectious Diseases · doi:10.1086/345744 · Cited by 428
Management of infective endocarditis
Habib, G. (2006) · Heart · doi:10.1136/hrt.2005.063719 · Cited by 211
Shorr, A. F., Kunkel, M. J., & Kollef, M. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki355 · Cited by 198 · cited 1×
“M 67 DM prosthetic AV VISA VAN ( 32 ) NA 42 died NA none”
Chien, J. W., Kucia, M. L., & Salata, R. A. (2000) · Clinical Infectious Diseases · doi:10.1086/313597 · Cited by 190 · cited 1×
“2000 ( 27 ) NA abdominal aortic repair, DM, ARF NA VRE VAN, ALF (NA) NA 42 cure 1 none”
Rubinstein, E., Isturiz, R., Standiford, H. C., Smith, L. G., Oliphant, T. H., Cammarata, S., Hafkin, B., Le, V., & Remington, J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.6.1824-1831.2003 · Cited by 177
Successful Treatment of Vancomycin-Resistant Enterococcus Endocarditis with Oral Linezolid
Babcock, H. M., Ritchie, D. J., Christiansen, E., Starlin, R., Little, R., & Stanley, S. (2001) · Clinical Infectious Diseases · doi:10.1086/319986 · Cited by 113
Cited by
Items 101–166 of 166
Forestier, E., Rémy, V., Mohseni-Zadeh, M., Lesens, O., Jauhlac, B., Christmann, D., & Hansmann, Y. (2006) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2006.11.014 · Cited by 14
New advances in management and treatment of cardiac implantable electronic devices infections
Russo, A., Serraino, R., Serapide, F., Trecarichi, E. M., & Torti, C. (2023) · Infection · doi:10.1007/s15010-023-02130-8 · Cited by 9
“The few data in the literature suggest good efficacy of lin-ezolid in treating IE as monotherapy or in combination with other antimicrobial agents, and treatment of IE with line-zolid (LNZ) was not associated with higher mortality rates [35–37].”
Good practice in antibiotic use: what about linezolid in a French university hospital?
Aubin, G. G., Lebland, C., Corvec, S., Thomaré, P., Potel, G., Caillon, J., & Navas, D. (2011) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-011-9576-0 · Cited by 7
“Linezolid was effective in these two indications as a bacteriostatic antibiotic [10, 11].”
BackgroundHeizmann, P., & Heizmann, W. R. (2007) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-007-1090-8 · Cited by 10
“Erste Daten lassen den Schluss zu, dass beispielsweise das Oxazolidinon Linezolid bei Endokarditiden mit multiresistenten grampositiven Erregern eine therapeutische Alternative darstellt [5, 9].”
BackgroundLinezolid-based therapy in Staphylococcus epidermidis endocarditis
Mylona, E. E., Fanourgiakis, P., Vryonis, E., Golfinopoulou, S., Skoutelis, A. T., Platsouka, E. D., & Chatzis, N. A. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.09.021 · Cited by 7
Wang, R., Niu, B., Ren, J., & Zhang, L. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-10837-2 · Cited by 6
“For minimal inhibitory concentrations, the PTA for streptococci is 100%/92% on day 1/day 5 for oral treatment, indicating the strong efficacy of linezolid against streptococcal infections [23, 24].”
Winston, L. G., Deck, D. H., & Bolger, A. F. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3291-5.50085-8 · Cited by 7
Oral Antibiotics for Bacteremia and Infective Endocarditis: Current Evidence and Future Perspectives
Eleftheriotis, G., Marangos, M. N., Lagadinou, M., Bhagani, S., & Assimakopoulos, S. F. (2023) · Microorganisms · doi:10.3390/microorganisms11123004 · Cited by 6
“The efficacy of oral linezolid in this setting had already been evaluated in a small number of cases since its first years on the market [152,153].”
BackgroundClinical pharmacology of linezolid: an oxazolidinone antimicrobial agent
Tan, T. Q., & Yogev, R. (2008) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.1.4.479 · Cited by 6
Methicillin-Resistant Staphylococcus aureus Bacteremia and Pneumonia
Ganesan, A. (2008) · Disease-a-Month · doi:10.1016/j.disamonth.2008.09.008 · Cited by 6
New therapeutic approach for the treatment for staphylococcal bacteremia and sepsis
Борисович, Б. В. (2014) · Epidemiology and Infectious Diseases · doi:10.17816/eid40824 · Cited by 5
Amiyangoda, C. G. K., Wimalaratna, H., & Bowatte, S. (2017) · BMC Research Notes · doi:10.1186/s13104-017-2907-z · Cited by 5
“Another systemic review was done to assess the outcome of treatment of infective endocarditis with linezolid in 2006 described only one patient with PVE due to MRSA who was successfully treated with linezolid without the need for valve replacement [12].”
New trends in infective endocarditis
Fariñas, M. C., Llinares, P., Almirante, B., Barberán, J., Colmenero, J., Garau, J., Gudiol, F., Hernández‐Quero, J., Mensa, J., Montejo, M., et al. (2011) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(11)70033-7 · Cited by 7
Safa, L., Afif, N., Hajjej, Z., Mehdi, D., & Ali, Y. M. (2016) · Pan African Medical Journal · doi:10.11604/pamj.2016.25.196.9476 · Cited by 5
Căliman-Sturdza, O. A. (2024) · Infectious diseases · doi:10.5772/intechopen.114918 · Cited by 5
Multidrug-Resistant Gram-Positive Bacterial Infections
Jung, Y., & Kim, H. B. (2015) · Korean Journal of Medicine · doi:10.3904/kjm.2015.88.5.487 · Cited by 5
“Vancomycin 치료 실패 때 구제요법으로 vancomycin에 다른 약제를 추가하는 것과 linezolid를 기반으로 하는 치료로 변경하는 것을 비교 하였을 때 후자에서 30일 사망률이 낮다는 보고도 있으나 [69] 다른 연구에서는 linezolid와 glycopeptide 치료 성적의 차 이가 없었고[70], 좌측 심내막염에서 linezolid의 성적이 나쁜 것으로 알려져 있어 주의가 필요하다[6,69,71].”
Palraj, R., Knoll, B. M., Baddour, L. M., & Wilson, W. R. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00083-7 · Cited by 4
Antibiotic therapy for treatment of infective endocarditis
Martí-Carvajal, A. J., Conterno, L. D. O., Hidalgo, R., Kwong, J. S., Georgoulas, P., & Salanti, G. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009880 · Cited by 4
Behandlung und Diagnostik infektiöser Endokarditiden mit negativen Blutkulturbefunden
Plicht, B., Naber, C. K., & Erbel, R. (2007) · Der Kardiologe · doi:10.1007/s12181-007-0005-5 · Cited by 3
Bacteriemia e infecciones endovasculares por grampositivos: nuevas opciones terapéuticas
Almirante, B. (2008) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1157/13123565 · Cited by 3
Linezolid – an oxazolidinone antibiotic
Patra, K. C., & Shah, P. (2012) · Pediatric Infectious Disease · doi:10.1016/j.pid.2012.07.001 · Cited by 3
Cleveland, K. O., & Memon, K. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr369 · Cited by 3
Multidrug-Resistant Organisms: Considerations in Antibiotic Selection and Administration
Arora, H. S., Gupta, S., Sutton, J. D., Abdel‐Haq, N., & Molloy, L. M. (2015) · Journal of Pediatric Intensive Care · doi:10.1055/s-0035-1556751 · Cited by 2
Kobayashi, S., Numata, R., Machino‐Ohtsuka, T., Suzuki, H., & Ishizu, T. (2025) · Internal Medicine · doi:10.2169/internalmedicine.5890-25 · Cited by 2
“Although daptomycin is typically considered the first-line alternative to VCM, LZD has shown high efficacy in selected cases and may be considered in cases of VCM intolerance or treatment failure (7, 8).”
Heintz, B. H., & Halilovic, J. (2010) · Hospital Pharmacy · doi:10.1310/hpj4512-916 · Cited by 2
“However, case reports and case series of successful linezolidtreated patients have been reported, suggesting that linezolid may be considered as a therapeutic alternative for the treatment of these infections in cases of treatment with standard therapy and/or limited available options.(22,44,54-61) Empiric use of line…”
BackgroundHermsen, E. D., Shull, S. S., Mitropoulos, I. F., Puumala, S. E., & Rupp, M. E. (2009) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0b013e318184d74e · Cited by 2
Individual patient data meta-analysis of prognostic factor studies
Abo-Zaid, G. (2011) · UPT. Syiah Kuala University Library (Syiah Kuala University) · Cited by 2
Howden, B. P. (2010) · CRC Press eBooks · doi:10.1201/b13787-81 · Cited by 2
Lowy, F. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-7020-6285-8.00142-8 · Cited by 2
The Efficacy of Linezolid for Methicillin-resistant Staphylococcus aureus Infectious Endocarditis
Kuwabara, F., Hirate, Y., Mori, S., Takanohashi, A., Yagami, K., Usui, M., Miyata, Y., & Yoshikawa, M. (2009) · Japanese Journal of Cardiovascular Surgery · doi:10.4326/jjcvs.38.280 · Cited by 2
Infective Endocarditis - aspects of pathophysiology, epidemiology, management and prognosis
Ekdahl, C. (2008) · DiVA (Linkoping University) · Cited by 2
Cañas, M.-A., de la Mària, C. G., García‐González, J., Jiménez, M. P., Marco, F., Sarasa, M., Meneses, M. H., Quintana, E., Falces, C., Tolosana, J. M., et al. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf149 · Cited by 1
Muñoz, D. L., Álvarez, M. I., Hales, D. R., & Zapata, L. V. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf235 · Cited by 1
Doering, M., & Elsner, D. (2014) · Springer eBooks · doi:10.1007/978-3-642-54953-3_53 · Cited by 1
Faller, E., & Jackson, A. (2022) · Journal of Chemotherapy · doi:10.1080/1120009x.2022.2145452 · Cited by 1
“There are several case series and reports of the agent being used successfully in endocarditis caused by resistant gram positive bacteria [55, 56], however there is insufficient data to support its use routinely.”
BackgroundRelai oral de l'antibiothérapie dans les endocardites infectieuses : un pas à franchir?
Jamard, S., Lacasse, M., Bernard, L., & Lemaignen, A. (2023) · Médecine et Maladies Infectieuses Formation · doi:10.1016/j.mmifmc.2023.03.381 · Cited by 1
Successful Treatment of Infective Endocarditis With Oral Antibiotics: A Case Report
Alsaeed, A. A., Alhaddad, M. J., Alkhalaf, A. M., Alkhudair, A., & Alqannas, N. K. (2023) · Cureus · doi:10.7759/cureus.43514 · Cited by 3
“, patients with IE) should be monitored for thrombocytopenia since it can develop in 31% of patients [25].”
BackgroundMitsutake, K., Shinya, N., Seki, M., Ohara, T., Uemura, K., Fukunaga, M., Sakai, J., Nagao, M., Sata, M., Hamada, Y., et al. (2024) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2024.02.027 · Cited by 1
Schell, C. M. (2019) · El Servicio de Difusión de la Creación Intelectual (National University of La Plata) · doi:10.35537/10915/73675 · Cited by 1
[Do we have adequate antimicrobials against methicillin-resistant Staphylococcus aureus?].
Bellido, J. L. M., & Rodríguez, J. Á. G. (2006) · PubMed · Cited by 1
Clinical Aspects of Multi-Drug Resistant Enterococci
Contreras, G., & Arias, C. A. (2011) · Springer eBooks · doi:10.1007/978-1-4614-1400-1_19
Present and Emerging Therapies for the Treatment of Drug-resistant Infections: Focus on Linezolid
Souli, M. (2010) · Clinical Medicine Reviews in Therapeutics · doi:10.4137/cmrt.s1571
Systemic Treatment Options for Medical Device-Associated Infection
Murillo, Ó., Lora-Tamayo, J., & Ariza, J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-1031-7_9
“limited ef fi cacy in a dif fi cult-to-treat infection where bactericidal killing is desirable [ 51, 77 ] .”
BackgroundLee, K., Kim, H., Kim, J., Lee, G., Lee, H., Kim, H., Kim, D., Sohn, I. W., & Pai, H. (2010) · Infection and Chemotherapy · doi:10.3947/ic.2010.42.6.415
Buzelé, R. (2014) · Journal des Anti-infectieux · doi:10.1016/j.antinf.2014.08.003
Traitement de l'endocardite bactérienne
Thirion, D. J. G., Williamson, D. R., Chaumard, N., Martineau, P., & Ducharme, M. P. (2008) · Elsevier eBooks · doi:10.1016/b978-2-294-06234-6.50053-3
Makinson, A., & Moing, V. L. (2008) · Annales de Cardiologie et d Angéiologie · doi:10.1016/j.ancard.2008.02.008
Epidemiology, treatment and outcome of Staphylococcus aureus bacteremia and endocarditis
Ruotsalainen, E. A. (2006) · Helda - University of Helsinki Institutional Repository · Cited by 1
Intensivtherapie bei infektiöser Endokarditis
Döring, M., & Elsner, D. (2015) · Springer eBooks · doi:10.1007/978-3-642-54675-4_64-1
Healthcare-associated Endocarditis by PVL-negative ST 72 SCCmec Type IV MRSA
Oh, H. M., Kim, K. U., Park, S. Y., Lee, J. S., Kim, J., & Eom, J. S. (2016) · Korean Journal of Medicine · doi:10.3904/kjm.2016.90.4.361
“- 364 따르면 지속적인 MRSA 혈증이 나타나거나 vancomycin 치료 실패일 경우 고용량 daptomycin을 고려하도록 권고하고 있으 며[7] 이외 2차 선택 항생제로는 linezolid를 제안하고 있다[8].”
Nakakura, I., Sekimoto, H., Yamashita, D., Horibe, A., Nakamura, K., Okada, H., Kohara, N., Sata, M., & Kamakura, S. (2010) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.36.502
INDIVIDUAL PATIENT DATA META A NALYSIS OF PROGNOSTIC FACTOR STUDIES
Mohammed, G., & Abo-Zaid, A. (2011)
Valent, F., Cecchi, A., Mozzon, R., & Troncon, M. G. (2011) · Giornale italiano di farmacia clinica
Advances in the Diagnosis and Treatment of Infective Endocarditis
Turner, R. B., & Schwartz, J. (2017) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-5225-2092-4.ch010
Infektiöse Endokarditis: Therapie und Prävention
Berkholz, A. P., Schwarzer, M., Bundschuh, M., & Groneberg, D. A. (2015) · Zentralblatt für Arbeitsmedizin Arbeitsschutz und Ergonomie · doi:10.1007/s40664-015-0020-5
“Neuere Substanzen mit einem einschlägigen antimikrobiellen Spektrum wie Linezolid und Daptomycin zeigen überzeugende Wirkung bei MRSA-Infektionen und gelten als Reserveantibiotika [7, 8].”
OBSOLETE: Infective Endocarditis in the 21st Century
Mehta, J. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.99720-4
Brust, J. C. M., & Lowy, F. D. (2010) · Elsevier eBooks · doi:10.1016/b978-0-323-04579-7.00136-2
대한감염학회, 대한화학요법학회, 대한임상미생물학회, 대한심장학회, 대한흉부외과학회, & Kim, T. H. (2011) · Infection and Chemotherapy
리네졸리드와 수술로 치료에 성공한 하지 동정맥 기형 감염과 동반 된 반복된 메티실린 내성 황색포도알균 패혈증 및 심내막염 1례
이강원, Kim, H., Jieun, K., 이길우, 이형탁, Kim, H., 김동찬, 손일웅, & Pai, H. (2010) · Infection and Chemotherapy
Doering, M., & Elsner, D. (2011) · Springer eBooks · doi:10.1007/978-3-642-16929-8_34
Infective Endocarditis in 21st Century
Kandasamy, V. V., Pant, S., & Mehta, J. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809657-4.99720-5
Manrique, J. C. R. (2020) · Repositorio Institucional (Pontificia Universidad Javeriana) · doi:10.11144/javeriana.10554.15427
Buckley, M. E. (2023) · Queensland University of Technology · doi:10.5204/thesis.eprints.242134 · Cited by 1
Combined Antimicrobial Therapy for Infective Endocarditis
Gomez-Villegas, S. I., Miller, W. R., & Arias, C. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-65839-6_16
Prosthetic valve endocarditis due to non-toxigenic Corynebacterium diphtheriae: A case report
Fakhfakh, A., Ferjani, S., Kanzari, L., Rehaiem, A., Hamzaoui, Z., Smaoui, O., Abdelmalek, R., Hedhli, H., Hosni, D., Zoubli, A., et al. (2026) · Acta Microbiologica et Immunologica Hungarica · doi:10.1556/030.2026.03046
Roland, T., & Yombi, J. C. (2026) · Pathogens · doi:10.3390/pathogens15090924
“However, its use may be limited by hematological toxicity (anemia, thrombocytopenia), peripheral neuropathy, and serotonin syndrome risk in patients co-prescribed selective serotonin reuptake inhibitors [23,24].”
Metadata
- Authors
- Falagas, M. E.
- Affiliations
- Henry Dunant Hospital (GR)
- Corresponding author
- Falagas, M. E.
- ORCID
- Falagas, M. E.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-05-30
- Volume
- 58
- Issue
- 2
- Pages
- 273-280
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2132751055
- Semantic Scholar
- 545a043e5b82976db958f7b3ba6dd6b97427306d
- Cited by
- 167
- References
- 43
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 4 · 2023: 10 · 2022: 1 · 2021: 2 · 2020: 4 · 2019: 6 · 2018: 4 · 2017: 6 · 2016: 4 · 2015: 12 · 2014: 11 · 2013: 3 · 2012: 10
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Antimicrobial Chemotherapy (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Surgery › Orthopedic Infections and Treatments
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Keywords
- linezolid, infective endocarditis, oxazolidinones, methicillin-resistant Staphylococcus aureus, vancomycin-intermediate Staphylococcus aureus, prosthetic valve endocarditis, bacteriostatic antibiotics, treatment efficacy, mortality, thrombocytopenia, combination antibiotic therapy
- MeSH terms
- Linezolid, Acetamides, Anti-Bacterial Agents, Endocarditis, Bacterial, Humans, Gram-Positive Bacterial Infections, Oxazolidinones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.